Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Non-randomised Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor) and Smoking (CYP1A2 Inducer) on the Pharmacokinetics of a Single Oral Dosing of AZD4635 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase I, Open-label, Non-randomised Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor) and Smoking (CYP1A2 Inducer) on the Pharmacokinetics of a Single Oral Dosing of AZD4635 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imaradenant (Primary) ; Fluvoxamine
  • Indications Cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 13 Apr 2023 Results reporting PK and safety from two phase 1 clinical studies (D8730C00007 and D8730C00002) published in the British Journal of Clinical Pharmacology
    • 05 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 11 Dec 2020 Planned End Date changed from 25 Nov 2020 to 23 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top